Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

Sofia Karageorgopoulou(National and Kapodistrian University of Athens), Christos Papadimitriou(National and Kapodistrian University of Athens)

BMC Cancer

June 28, 2017

10.1186/s12885-017-3435-x

Cited by 20

Related Papers

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer

|ESMO Open|2019|50

Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group

|Cancers|2021|41

Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group

|ESMO Open|2020|38

Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges

|Frontiers in Oncology|2022|35